183 related articles for article (PubMed ID: 25147058)
1. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.
Boss C; Roch-Brisbare C; Steiner MA; Treiber A; Dietrich H; Jenck F; von Raumer M; Sifferlen T; Brotschi C; Heidmann B; Williams JT; Aissaoui H; Siegrist R; Gatfield J
ChemMedChem; 2014 Nov; 9(11):2486-96. PubMed ID: 25147058
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Mercer SP; Roecker AJ; Garson S; Reiss DR; Meacham Harrell C; Murphy KL; Bruno JG; Bednar RA; Lemaire W; Cui D; Cabalu TD; Tang C; Prueksaritanont T; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2013 Dec; 23(24):6620-4. PubMed ID: 24215892
[TBL] [Abstract][Full Text] [Related]
4. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
[TBL] [Abstract][Full Text] [Related]
5. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat.
Steiner MA; Sciarretta C; Brisbare-Roch C; Strasser DS; Studer R; Jenck F
Psychoneuroendocrinology; 2013 Apr; 38(4):560-71. PubMed ID: 22917622
[TBL] [Abstract][Full Text] [Related]
6. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
7. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
8. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.
Hoch M; van Gorsel H; van Gerven J; Dingemanse J
J Clin Pharmacol; 2014 Sep; 54(9):979-86. PubMed ID: 24691844
[TBL] [Abstract][Full Text] [Related]
9. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
10. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
11. Orexin receptor antagonists--a patent review (2010 to August 2014).
Boss C
Expert Opin Ther Pat; 2014 Dec; 24(12):1367-81. PubMed ID: 25407283
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
Steiner MA; Gatfield J; Brisbare-Roch C; Dietrich H; Treiber A; Jenck F; Boss C
ChemMedChem; 2013 Jun; 8(6):898-903. PubMed ID: 23589487
[TBL] [Abstract][Full Text] [Related]
13. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule antagonists of the orexin receptors.
Christopher JA
Pharm Pat Anal; 2014; 3(6):625-38. PubMed ID: 25489915
[TBL] [Abstract][Full Text] [Related]
15. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
[TBL] [Abstract][Full Text] [Related]
17. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
19. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders.
Xu TR; Yang Y; Ward R; Gao L; Liu Y
Cell Signal; 2013 Dec; 25(12):2413-23. PubMed ID: 23917208
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
